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Diabetes is characterized by ‘‘glucotoxic’’ loss of
pancreatic b cell function and insulin content, but
underlying mechanisms remain unclear. A mouse
model of insulin-secretory deficiency induced by b
cell inexcitability (KATP gain of function) demon-
strates development of diabetes and reiterates the
features of human neonatal diabetes. In the diabetic
state, b cells lose their mature identity and dediffer-
entiate to neurogenin3-positive and insulin-negative
cells. Lineage-tracing experiments show that dedif-
ferentiated cells can subsequently redifferentiate
to mature neurogenin3-negative, insulin-positive b
cells after lowering of blood glucose by insulin ther-
apy. We demonstrate here that b cell dedifferentia-
tion, rather than apoptosis, is the main mechanism
of loss of insulin-positive cells, and redifferentiation
accounts for restoration of insulin content and anti-
diabetic drug responsivity in these animals. These
results may help explain gradual decrease in b cell
mass in long-standing diabetes and recovery of
b cell function and drug responsivity in type 2 dia-
betic patients following insulin therapy, and they
suggest an approach to rescuing ‘‘exhausted’’ b
cells in diabetes.
INTRODUCTION
Type 2 diabetes is characterized by b cell dysfunction, the
mechanism of which is controversial (Ahlqvist et al., 2011; Butler
et al., 2003; Hur et al., 2010; Nolan and Prentki, 2008; Prentki
and Nolan, 2006; Puri and Hebrok, 2012; Robertson et al.,
2004; Talchai et al., 2012b; Wajchenberg, 2007). When faced
with persistent hyperglycemia, the normal pancreatic b cell first
responds with compensatory increase in insulin secretion and b
cell mass (Ahre´n, 2005; Bernal-Mizrachi et al., 2000; Heit et al.,
2006; Jhala et al., 2003). However, chronic hyperglycemia
gradually also leads to a paradoxical ‘‘glucotoxic’’ loss of b
cell mass and insulin content that has typically been attributed
to enhanced b cell apoptosis (Butler et al., 2003; Lupi and Del
Prato, 2008; Poitout and Robertson, 2008; Porat et al., 2011;872 Cell Metabolism 19, 872–882, May 6, 2014 ª2014 Elsevier Inc.Prentki and Nolan, 2006). Progressive deterioration in b cell
function and marked reduction of b cell mass are classic find-
ings in type 2 diabetic human islets, regardless of the therapy
(Cnop et al., 2005; Del Prato et al., 2007; Sakuraba et al.,
2002; UK Prospective Diabetes Study Group, 1998a, 1998b),
and reduced glucose-stimulated insulin secretion (GSIS) as
well as increased rates of b cell apoptosis and decreased b
cell survival have been detected in islets from human diabetic
pancreases (Butler et al., 2003; Tanaka et al., 2002; Weinberg
et al., 2007). In general, however, the impairment of b cell func-
tion in diabetic islets may be much greater than could be ex-
plained by the observed increase in the rate of apoptosis (Butler
et al., 2003), and b cell death may not be the main contributor to
the marked loss of b cell mass.
An alternative mechanism for diabetic loss of insulin content
has recently received attention (Talchai et al., 2012b). The tran-
scription factor FoxO1 is a major determinant of cell fate in
enteroendocrine cells. In islets that lack FoxO1 in b cells, Tal-
chai et al. (2012b) demonstrated b cell dedifferentiation to
endocrine progenitor-like cells during stress-induced hyper-
glycemia. In addition to processes impinging on b cell survival
and, hence, on islet mass, b cell dedifferentiation can also be
observed in vitro (Weinberg et al., 2007). Dedifferentiation
in common forms of b cell failure has also been inferred from
partial pancreatectomy studies (Jonas et al., 1999). Together,
these studies raise the possibility that dedifferentiation and
conversion into other endocrine cell types may be an underre-
cognized mechanism of b cell failure in multiple forms of dia-
betes and, moreover, that this process might conceivably be
reversible.
Insulin secretory failure due to inexcitability is a major cause of
monogenic neonatal diabetes (Flanagan et al., 2009; Gloyn et al.,
2004) and a prominent contributor to human type 2 diabetes
(Nielsen et al., 2003; Riedel et al., 2005; Villareal et al., 2009).
Our studies reveal that a major mechanism of b cell loss in
diabetes resulting from secretory failure due to inexcitability
(Remedi et al., 2009) is also dedifferentiation. Evenmore striking,
additional experiments show that intensive insulin therapy, by
reversing the hyperglycemia, leads to redifferentiation to mature
b cells. These results provide a potential explanation for gradual
decrease in b cell mass in long-standing and poorly controlled
human diabetes, as well as for recovery of b cell function and
sulfonylurea responsivity, as can be observed in type 2 diabetic
patients after intensive insulin therapy (Torella et al., 1991; Waj-
chenberg, 2007).
AB
Figure 1. KATP-GOF Mice Develop Profound Diabetes
(A) Fed blood glucose (individual traces) from control (black squares) and KATP-
GOF (white squares) mice after tamoxifen induction of transgene expression.
(B) Fasting blood glucose, plasma insulin, and total insulin content per
pancreas in control (black) and KATP-GOF (white) mice 30 days after tamoxifen
induction (n = 10–12 mice per group, mean ± SEM; *p < 0.05, with respect to
control).
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KATP-GOF Mice Develop Diabetes with Dramatic Loss of
Insulin Content
Following tamoxifen injection, 2-month-old Pdx1PBCreERTM
Kir6.2[K185Q,DN30] (KATP-GOF) mice express the ATP-insensi-
tive Kir6.2[K185Q,DN30] transgene, as well as an EGFP reporter.
The animals develop severe diabetes within 2 weeks after
tamoxifen induction (Figure 1A), as a result of the loss of
glucose-dependent insulin secretion (Remedi et al., 2009,
2011). Fed and fasting blood glucose rise to >500 mg/dl in all
KATP-GOF mice within 20 days after tamoxifen induction of
transgene expression and remain high thereafter (Figures 1A
and 1B). Insulin secretion is extremely low, and insulin content
is markedly decreased in KATP-GOF animals with respect to con-
trol mice (Figure 1B). These findings thus reiterate key features of
human neonatal diabetes resulting from severe KATP-GOFmuta-
tions (Flanagan et al., 2009; Gloyn et al., 2004; Matthews et al.,
1998; Nolan et al., 2011; Pearson et al., 2006; Shimomura
et al., 2007), as well as the consequences of KATP-GOF that
result from the type 2 diabetes-associated polymorphism
(E23K) in the Kir6.2 subunit of the KATP channel (Nielsen et al.,
2003; Villareal et al., 2009).CInsulin Content and Insulin-Positive b Cells Are
Restored in KATP-GOF Diabetic Mice after Chronic
Insulin Therapy
Following the induction of diabetes in KATP-GOFmice, the reduc-
tion of plasma insulin level was accompanied by gradual loss of
islet insulin content and insulin-positive b cells (Figures 2B and
2C) (Remedi et al., 2009). We previously showed that this sec-
ondary loss could be avoided bymaintenance of normoglycemia
during and following disease induction, either by syngeneic
islet transplantation or by sulfonylurea treatment, if initiated at
disease onset (Remedi et al., 2009, 2011). However, once the
disease has developed, sulfonylurea treatment is relatively inef-
fective, readily explained as a consequence of themarked loss of
islet insulin content that rapidly develops (Remedi et al., 2009).
Similar processesmay also underlie gradual loss of drug respon-
sivity in long-term or poorly controlled human diabetes, and this
raises the possibility that loss of insulin content might actually be
restorable if glucose levels are normalized and that drug respon-
sivity may then also be restored.
To examine this possibility directly, we divided severely dia-
betic KATP-GOF mice (blood glucose >500 mg/dl for 3 weeks)
into two groups: (1) untreated and (2) chronically treated with in-
sulin by implantation of slow-release insulin pellets in an attempt
to restore normoglycemia. Untreated KATP-GOF mice main-
tained persistently elevated blood glucose (Figure 2A). Insulin-
treated KATP-GOF mice all demonstrated a marked reduction
in blood glucose (Figure 2A), although the degree of normaliza-
tion was variable; some mice essentially achieved normoglyce-
mia with only one pellet implanted, whereas others required a
second pellet to achieve a sustained lowering of blood glucose
levels (Figure 2A).
In untreated diabetic KATP-GOF pancreases, immunohisto-
chemistry reveals disrupted architecture with a marked loss of
insulin content and insulin-positive b cells in islets from KATP-
GOF mice that were sacrificed at 30 days following tamoxifen
induction (Figures 2B and 2C). However, insulin content and in-
sulin-positive b cells were fully restored in islets from the second
set of diabetic KATP-GOF mice that were treated with insulin by
implantation of slow-release pellets at 30 days following disease
induction and then sacrificed 40 days later (i.e., after 40 days of
insulin treatment; Figure 2C). Notably, islets from insulin-treated
mice, in which normalization of glycemic control was incom-
plete, showed a less pronounced recovery of insulin content
than islets from mice in which glucose was almost fully normal-
ized (Figure 2C). Moreover, total insulin content per pancreas,
which was markedly reduced from 574 ± 21 ng in control mice
to 102 ± 6 ng in untreated KATP-GOF mice (Figure 1B), was
almost completely restored (to 495 ± 14 ng) in insulin-treated
KATP-GOF mice.
b-Cell Death May Not Explain theMarked Loss of Insulin
Content and Insulin-Positive b Cells in KATP-GOF Islets
Increased apoptosis may contribute to b cell loss in type 2 dia-
betes (Butler et al., 2003; Poitout and Robertson, 2008; Prentki
and Nolan, 2006), and the marked reduction of insulin content
in diabetic KATP-GOF islets (Figures 2B and 2C) raises the possi-
bility that increased apoptosis might be responsible. Apoptosis
was therefore assessed in pancreatic sections from control
and KATP-GOF (untreated and insulin-treated) mice by terminalell Metabolism 19, 872–882, May 6, 2014 ª2014 Elsevier Inc. 873
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Figure 2. Insulin Therapy Restores Endoge-
nous Insulin Content in Diabetic KATP-GOF
Mice
(A) Fed blood glucose in control (average, black
dashed line) and in KATP-GOF untreated (white,
dashed line) and insulin-treated (white, solid line)
mice after tamoxifen induction of transgene
expression. Big arrow indicates first insulin pellet
implantation, and small arrows a second insulin
pellet implanted in individual mice as necessary
(blood glucose > 400 mg/dl).
(B) Panels on the left show high-magnification
sections of pancreases stained with hematoxylin
and eosin from control and KATP-GOF untreated
and insulin-treated mice. Bar graph on the right
indicates the pancreatic b cell area from (C) in
control (black), KATP-GOF untreated (white), and
insulin-treated (pink) mice.
(C) Insulin immunofluorescence (left) and insulin
content (right) per islet in control (black) and KATP-
GOF mice, untreated 30 days after tamoxifen in-
jection (white) or insulin treated (70 days after
tamoxifen, 40 days after insulin pellet implantation;
pink) (n = 3–6 mice per group, mean ± SEM). In-
sulin-treated KATP-GOF mice were divided in two
groups at the time of sacrifice following the criteria
of blood glucose levels: near normoglycemic and
normoglycemic. Significant differences: *p < 0.05,
with respect to control mice and #p < 0.05, with
respect to untreated KATP-GOF mice.
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(TUNEL) andcleavedcaspase-3 assays. TUNELstaining showed
only a slight (nonsignificant) increase in the number of apoptotic
cells within diabetic islets from untreated KATP-GOF mice,
compared with islets from control and insulin-treated mice (Fig-
ure 3A). Since TUNEL detects DNA strand breaks in terminal
cell stages, it is possible that the frequency of TUNEL-positive
cells does not accurately reflect the level of apoptosis in these
samples; therefore, we additionally assessed the levels of
cleavedcaspase-3.Cleavedcaspase-3positivity showedasmall
but significant increase in untreated KATP-GOF islets but was not
different between control and insulin-treated islets (Figure 3B).
Hyperglycemia Drives Dedifferentiation of KATP-GOF
Pancreatic b Cells to an Insulin-Negative,
Neurogenin3-Positive Phenotype
Given the only slight increase in apoptosis in even severely dia-
betic KATP-GOF islets, the recent findings of Talchai et al. (2012b)874 Cell Metabolism 19, 872–882, May 6, 2014 ª2014 Elsevier Inc.raise the possibility that dedifferentiation
might be an alternative mechanism un-
derlying the dramatic loss of insulin-posi-
tive b cells in these mice. Pancreatic
sections from untreated and insulin-
treated KATP-GOF mice were immuno-
stained for neurogenin3 (Ngn3), a marker
of islet progenitor cells (Gu et al., 2002; Xu
et al., 2008). There was essentially no
Ngn3 positivity in control islets, but we
observed a high number of dedifferen-
tiated, Ngn3 positive, cells in diabeticKATP-GOF mouse islets using both Santa Cruz and BCBC
Ngn3 antibodies (Figure 4; Figure S3A available online). Impor-
tantly, almost all Ngn3-positive cells were insulin-negative (Fig-
ure 4). These results indicate that, in the diabetic condition, a sig-
nificant number of mature insulin-containing b cells are replaced
by insulin-negative and Ngn3-positive cells, whichmight actually
have arisen by dedifferentiation from mature b cells. In order to
lineage trace the loss of insulin-positive cells as well as the origin
of Ngn3-positive cells, pancreatic sections were double immu-
nostained for insulin or Ngn3 and EGFP, which is coexpressed
with the KATP-GOF mutant transgene following tamoxifen induc-
tion (Remedi et al., 2009) and therefore indicates cells that are, or
were, mature insulin-producing b cells. Double immunostaining
for insulin and EGFP shows that almost all cells in the islet core
are EGFP positive in untreated diabetic KATP-GOF islets, but
only 40% express insulin (Figure 5A). Moreover, in these
severely diabetic KATP-GOF islets, essentially all Ngn3-positive
cells also express EGFP (Figure 5B), indicating that the
AB
Figure 3. Small Increase in Apoptosis in
KATP-GOF Diabetic Mice
(A and B) Representative pancreatic sections (left
panels) and quantification of apoptosis (bar graphs
at right) from control (black) and KATP-GOF un-
treated (white) and insulin-treated (pink) mice
immunostained for insulin (red) and apoptosis
(green) using TUNEL (A) and cleaved caspase-3
(B). Data represent mean ± SEM, n = 4 mice per
group, five pancreatic sections per mouse. *p <
0.05, with respect to control. arb., arbitrary units.
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providing compelling evidence for dedifferentiation as the pri-
mary mechanism for the loss of b cell phenotype. A question
arises as to what happens to the insulin, since these islets are
electrically inexcitable and lack glucose-dependent insulin
secretion. Clearly, the cells are depleted of insulin, but this is pre-
sumably either through intracellular degradation or depletion
through basal secretion once the cells turn off insulin production
(i.e., as they dedifferentiate). To examine potential plasticity
and pluripotency of b cell dedifferentiation, we also looked for
expression of other stem cell markers in diabetic KATP-GOF
islets. Quantitative real-time PCR shows an increase in mRNA
expression levels of islet progenitor markers Ngn3, Nanog, and
L-Myc (Figure S2D) and a corresponding decrease in the levels
of b cell-specific markers Pdx1, Nkx6.1, and MafA (Figure S2C)
in diabetic islets, consistent with b cell dedifferentiation to endo-
crine progenitor cells in the diabetic state. Immunohistologically,
we detected Oct4, Nanog, and Nestin expression in control
embryonic day (E) 15.5 fetal tissue, although we were unable
to detect these markers in adult KATP-GOF diabetic islets (Fig-
ure S2B); thus, we cannot confirm that the elevated message
levels are reflected in elevated protein levels.
Redifferentiation to Insulin-Producing b Cells following
Chronic Lowering of Blood Glucose
As shown earlier, Ngn3-positive cells were not observed in islets
from control islets, nor were they observed in insulin-treated
KATP-GOF islets from mice after reduction of blood glucose
levels (Figure 5B). Instead, following lowering of blood glucose
in treated mice, EGFP and insulin are again expressedCell Metabolism 19, 872throughout the core (Figure 5). This
suggests that substantial reduction of
systemic hyperglycemia—in this case,
by insulin therapy—actually permits
redifferentiation of the Ngn3-positive
cells to mature, insulin-containing b cells.
Tamoxifen can remain in the body for an
extended period and may continue to
label significant numbers of cells for a
few weeks after treatment (Reinert et al.,
2012), but the finding that almost all cells
in the islet core stain positive for the EGFP
reporter, 70 days after initial tamoxifen in-
duction (Figure 5) strongly argues that
these were the same cells that were orig-
inally induced to express EGFP asmatureb cells. Notably, mRNA expression levels of the b cell markers
Pdx1, Nkx6.1, and MafA are restored to normal levels in insu-
lin-treated islets (Figure S2C), with a concomitant decrease in
the progenitor markers Ngn3, Oct4, Nanog, and L-Myc (Fig-
ure S2D) consistent with dedifferentiated cells redifferentiating
to mature b cells.
To investigate the alternative possibility that an abnormally
high b cell proliferation might underlie restoration of the insulin-
expressing cells, we performed immunostaining for the cell cycle
marker Ki67. The fraction of Ki67-positive b cells per islet was not
different between control, diabetic, or treated conditions (Fig-
ure S1), providing evidence of similarly low rates of proliferation
in each and suggesting that the reappearance of mature b cells
is not likely to be the result of proliferation of residual, preexisting
b cells.
Endogenous Insulin Secretion in Response to
Sulfonylureas, but Not to Glucose, Is Restored in
Redifferentiated Islets from Insulin-Rreated KATP-GOF
Mice
The aforementioned results imply that the restoration of islet in-
sulin content, following normalization of glycemia, results from
redifferentiation of preexisting KATP-GOF b cells that had dedif-
ferentiated to insulin-negative, Ngn3-positive cells. If this is cor-
rect, then these cells, in addition to still expressing EGFP, should
also still be expressing the KATP-GOF transgene and, hence,
should remain electrically inexcitable and nonresponsive to
glucose but responsive to sulfonylureas. Insulin secretion in
low (1 mM) glucose or in response to the sulfonylurea glibencla-
mide was not different between control and insulin-treated–882, May 6, 2014 ª2014 Elsevier Inc. 875
Figure 4. bCell Dedifferentiation in Severely
Diabetic KATP-GOFMice and bCell Rediffer-
entiation in Islets from KATP-GOF Insulin-
Treated Mice
Panels at left show representative pancreatic
sections from control and KATP-GOF untreated
and insulin-treated mice double immunostained
for insulin (green) and Ngn3 (Santa Cruz antibody;
red). White-bordered insets show Ngn3-positive
and insulin-negative cells within islets. Blue-
bordered insets show occasional Ngn3-positive
and insulin-positive cells. Panel at top right shows
Ngn3 positivity in E15.5 fetal tissue. Bar graph at
bottom right indicates percentage of Ngn3-posi-
tive cells, either insulin negative (Ins; red) or in-
sulin positive (Ins+; light blue from each condition;
mean ± SEM). Data represent n = 5–8 mice per
group, five pancreatic sections per mouse. Sig-
nificant differences: *p < 0.05, with respect to
control and KATP-GOF insulin-treated mice.
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aforementioned prediction, robust glucose-dependent secretion
was present in control islets but not in insulin-treated and control
islets (Figure 6A). Together with the immunohistochemical find-
ings, these results provide strong evidence that dedifferentiated
and then redifferentiated cells were originally KATP-GOF mutant
b cells.
Sulfonylurea-Dependent Insulin Secretion Is Reinstated
in KATP-GOF Mice after Insulin Therapy
Restoration of sulfonylurea-sensitive insulin secretion in insulin-
treated KATP-GOF islets would also suggest that in vivo sulfonyl-
urea-sensitive secretion should also be restored. Artifactually
high insulin levels are measured in the blood of insulin-treated
mice (3,251 ± 487 ng/ml), which obviates assessment of the
levels of endogenous insulin itself. We therefore measured
C-peptide levels in mice following injection with the sulfonylurea
glibenclamide. Control mice all showed high (400–600 pmol/l)
plasma C-peptide levels (Figure 6B). Thirty days after tamoxifen
injection, untreated diabetic KATP-GOF mice showed very low
levels of C-peptide (30 days after treatment; Figure 6B), consis-
tent with the marked increase in the number of dedifferentiated
Ngn3-positive cells (Figures 4 and S3A) and decrease in insulin
content within their islets (Figures 2B and 2C). However, C-pep-
tide levels were considerably higher in the same KATP-GOF mice
after a subsequent 10 days with insulin treatment (total, 40 days
after tamoxifen injection; Figure 6B) and even higher after
40 days of insulin treatment (total, 70 days after tamoxifen injec-
tion; Figure 6B). In a subset of KATP-GOF mice, C-peptide levels
were measured both before and 30 min after glibenclamide in-
jection (Figure 6C). In untreated diabetic KATP-GOF mice, there
was no significant response to the drug, but there was increas-
ingly marked glibenclamide response with time after insulin
treatment. These results nicely correlate with the increase in
insulin content and number of insulin-positive b cells that was
observed in insulin-treated islets. Notably, and as predicted,
both KATP-GOF untreated or insulin-treated (10 days or
40 days of insulin treatment) mice demonstrated low C-peptide
levels in fed conditions, and only mice that had been treated876 Cell Metabolism 19, 872–882, May 6, 2014 ª2014 Elsevier Inc.with insulin showed restoration of C-peptide release in response
to sulfonylurea stimulation (Figure 6C; C-peptide release after
glibenclamide over basal). Together, these results demonstrate
that restoration of b cell insulin positivity and islet insulin content
in diabetic mice by insulin therapy indeed leads to reestablish-
ment of antidiabetic drug responsivity.
Dedifferentiated b Cells Do Not Transdifferentiate to
Glucagon-Producing a Cells
As reported previously (Remedi et al., 2009), severely diabetic
KATP-GOF mice demonstrate a significant increase in glucagon
immunoreactive area, as well as elevated plasma glucagon
levels, but all of these are substantially reversed after insulin ther-
apy (Figure 7). By lineage tracing analysis, we can examine
the possibility of transdifferentiation of EGFP-positive b cells
to glucagon-producing a cells via Ngn3-positive progenitors.
Pancreatic sections from control and KATP-GOF mice were dou-
ble stained for glucagon and EGFP (whichwill indicate KATP-GOF
former b cells) (Figure 7A). The number of glucagon-positive cells
increases in the diabetic state, but only a very small number of
cells costain for both glucagon and EGFP in untreated or treated
islets (Figures 7A and 7B), indicating that the increase in the
number of a cells in these islets is not substantially attributable
to conversion from b cells.
Rip-KATP-GOF Mice Also Develop Severe Diabetes and
Show Similar Dedifferentiation of b Cells and
Redifferentiation after Insulin Therapy
Pdx1 is also expressed in ductal and even acinar cells, raising
the formal possibility that newly formed b cells might derive
from non-b cells that express Pdx1 during tamoxifen treatment.
We therefore performed similar experiments to those described
earlier on mice in which the KATP-GOF transgene (Kir6.2
[K185Q,DN30]) was expressed under the control of the rat insulin
promoter (Rip) in Rip-Cre-expressing mice (Rip-KATP-GOF). Rip-
KATP-GOF mice show hyperglycemia immediately after birth,
with development of severe diabetes over time (Remedi et al.,
2009), similar to Pdx KATP-GOF mice. Severely diabetic, 75-
day-old Rip-KATP-GOF mice were implanted with slow-release
AB
Figure 5. Dedifferentiated and Redifferenti-
ated Islet Cells Are Originated from Former
Adult b Cells
(A and B) Left panels show representative images
of double immunostaining for EGFP (indicating
transgene expression in pancreatic b cells) and
insulin (A) or Ngn3 (B) on pancreatic sections from
control and both untreated and insulin-treated
KATP-GOF mice. Insets show representative cells.
Right panels indicate the percentage of the im-
munopositive area of the islet insulin and EGFP (A)
or of Ngn3 and EGFP (B) (mean ± SEM). Data
represent n = 5 mice per group, five pancreatic
sections per mouse.
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40 days (Figure S3A). Islet insulin content, which was markedly
reduced compared to that in age-matched littermates, was
also dramatically restored following insulin treatment (Figures
S3B and S3C). There was again a striking increase in Ngn3-pos-
itive/insulin-negative cells in untreated Rip-KATP-GOF mice that
disappeared following treatment (Figures S3D and S3E). Again,
Ngn3-positive cells and insulin-positive cells both costained
with EGFP-positive cells, again providing compelling evidence
that dedifferentiated as well as redifferentiated cells originated
from former b cells (Figure S3E). Glucagon immunostaining
also demonstrated a significant increase in a cell population in
diabetic Rip-KATP-GOF mice (Figure S3F).
DISCUSSION
This study shows that (1) loss of insulin content during the pro-
gression of diabetes that results from b cell secretory failure oc-
curs primarily through glucotoxic b cell dedifferentiation rather
than apoptosis and that (2) restoration of normoglycemia results
in redifferentiation to insulin-positive b cells.
Controlling Blood Glucose Is Enough to Reverse
Glucotoxicity in Diabetes
It is generally well established that hyperglycemia negatively af-
fects b cell secretory capacity, but the underlying mechanisms
and treatability are not completely understood. A progressive
deterioration in b cell function is a common finding in patients
with both type 2 diabetes (Matthews et al., 1998; Nolan et al.,
2011; Rhodes, 2005; Sakuraba et al., 2002; UK Prospective Dia-Cell Metabolism 19, 872betes Study Group, 1998a, 1998b) and
KATP-dependent monogenic diabetes
(Pearson et al., 2006). We previously
demonstrated that chronic hyperglyce-
mia gradually leads to a dramatic loss
of insulin-positive cells and insulin con-
tent in our KATP-GOF mouse model of
neonatal diabetes (Remedi et al., 2009),
correlating with the findings obtained in
other rodent models of diabetes (Girard
et al., 2009; Jonas et al., 2009; Lay-
butt et al., 2003; Porat et al., 2011; Talchai
et al., 2012b). In this article, we demon-
strate that chronic insulin treatment notonly normalizes blood glucose in diabetic KATP-GOF mice but
also dramatically restores insulin content and insulin-positive
b cells. The secondary consequences of diabetes and their
reversal were strikingly reflected in vivo by loss, and reversal,
of insulin and C-peptide release in response to injected gliben-
clamide and in isolated islets by restored glibenclamide- and
KCl-dependent insulin secretion. These results suggest that
relieving b cells from systemic hyperglycemia may actually
restore insulin content and thereby improve b cell drug
responsiveness.
There has beenmuch interest in the notion that b cells become
‘‘exhausted’’ due to the excess demands of secretion induced
by hyperglycemia in the diabetic state and that b cell ‘‘rest’’ via
exogenous insulin treatment permits restoration of b cell function
in type 2 diabetic patients (Alvarsson et al., 2008; Greenwood
et al., 1976; Qvigstad et al., 2004; Torella et al., 1991; Weng
et al., 2008). The present results show that insulin therapy, by
correcting the systemic diabetes, leads to restoration of endog-
enous islet insulin content and antidiabetic drug responsivity in
islets that are intrinsically inexcitable and are, therefore, chroni-
cally low in [Ca2+]i and do not secrete insulin in response to
glucose (Benninger et al., 2011; Remedi et al., 2009). Thus, it
must be that somewhere upstream of excitability and secretion
is being affected. As we showed previously (Benninger et al.,
2011), glucose-dependent metabolism, as assessed by NAD(P)
H autofluorescence, is actually elevated in diabetic KATP-GOF is-
lets, potentially a consequence of chronic in vivo hyperglycemia.
Thus, we suggest that it is ‘‘rest’’ from hyperstimulation of meta-
bolism, rather than ‘‘rest’’ from hyperexcitability and secretion,
that permits b cell recovery of insulin-positive cells and insulin–882, May 6, 2014 ª2014 Elsevier Inc. 877
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Figure 6. Glibenclamide-Dependent C-Pep-
tide Release Is Restored Only in KATP-GOF
Insulin-Treated Mice
(A) Insulin secretion from islets isolated from con-
trol and KATP-GOF untreated and insulin-treated
mice (70 days after tamoxifen, 40 days on insulin
therapy). Islets were incubated in low (1 mM) and
high (23 mM) glucose (gluc), and in the presence of
the sulfonylurea glibenclamide (glib) (1 mM) or the
depolarizing agent KCl (30 mM). Data represent
mean ± SEM. Significant differences: #p < 0.05,
with respect to control under the same condition,
and *p < 0.05, with respect to 1 mM glucose within
the same group.
(B) Plasma C-peptide (individual values) 30 min
after glibenclamide stimulation in control mice
(black circles, 30 days after treatment [Tx]; black
squares, 40 days after Tx; and black triangles,
70 days after Tx), KATP-GOF mice untreated
30 days after tamoxifen injection (white, 30 days
after Tx [30d]) and KATP-GOF mice treated with
insulin for 10 days ([10d insulin] total, 40 days after
Tx; light pink) and 40 days ([40d insulin] total,
70 days after Tx; dark pink).
(C) Delta plasma C-peptide in response to gliben-
clamide in KATP-GOF untreated (white) and KATP-
GOF insulin-treated (10 and 40 days, light pink and
dark pink, respectively) mice (n = 5–9 mice per
group, experiments made in triplicates, mean ±
SEM). Significant differences: *p < 0.05 with
respect to KATP-GOF untreated mice.
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of this improvement might also be key to the beneficial effects
of insulin therapy and tight glycemic control in type 2 diabetic
patients (Alvarsson et al., 2003; Ilkova et al., 1997; UK Prospec-
tive Diabetes Study Group, 1998a, 1998b; Wajchenberg, 2007;
Weng et al., 2008).
Apoptosis versus Dedifferentiation as a Response to
Hyperglycemia
In this article, we demonstrate that hyperglycemia-induced glu-
cotoxicity, with marked loss of islet insulin content and insulin-
positive b cells, is accompanied by a small increase of apoptosis
(Figure 3), similar to the levels of apoptosis detected in human
diabetic islets (Butler et al., 2007; Rahier et al., 2008). However,
the number of cells exhibiting positive TUNEL staining or cleaved
caspase-3 is markedly less than the number of insulin-negative
cells (Figure 3), suggesting that b cell dedifferentiation, rather
than apoptosis, may be the major mechanism underlying the
loss of insulin positivity. Ngn3 expression is essentially undetect-
able in islets from control mice, reportedly present at very low
levels in adult mouse pancreases (Wang et al., 2009), but it is
clearly elevated in insulin-negative cells of untreated KATP-GOF
islets (Figures 4 and S2A); and, at least at the messenger level,
Ngn3 expression as well as that of other progenitor markers,
Nanog and L-Myc, is elevated in diabetic islets form KATP-GOF
diabetic mice (Figure S2D). These results are very comparable
to the finding of marked increase in the number of dedifferenti-
ated cells within stressed FoxO1-deficient and insulin-resistant878 Cell Metabolism 19, 872–882, May 6, 2014 ª2014 Elsevier Inc.GIRKO and db/db models of type 2 diabetes (Talchai et al.,
2012b). As Talchai et al. suggested, such dedifferentiation,
rather than a truly degenerative state, may provide an advantage
to the islet and, as we show later, a potential route to the ultimate
reversibility of islet demise. The underlying mechanism for the
dedifferentiation is still not clear but might be linked to the down-
regulation of FoxO1 following hyperglycemia-induced oxidative
stress (Benninger et al., 2011; Kitamura et al., 2005; Talchai
et al., 2012a). The phenomenon may provide an explanation
for the slow decline of b cell mass in human diabetes (Rahier
et al., 2008), although no changes in mRNA expression levels
of Ngn3 or other stem cell markers were detected in a recent
study (Guo et al., 2013) of human type 2 diabetic islets (with
the exception of Oct4, which increased significantly). The dra-
matic decrease in mRNA levels of the b cell transcription factors
Pdx1, MafA, and Nkx6.1 in our diabetic KATP-GOF mice (Fig-
ure S2C) correlates well with the marked reduction in these tran-
scription factors in both human and mouse type 2 diabetic islets
(Guo et al., 2013; Talchai et al., 2012b), reflecting loss of b cell
identity in glucotoxic conditions in vivo.
Redifferentiation as a Response to Normalization of
Glycemia
We demonstrate here a dramatic recovery of insulin-positive b
cells and islet insulin content—and, hence, sulfonylurea respon-
sivity—after insulin therapy in KATP-GOF mice (Figures 2, 5, and
6). The level of this recovery is proportional to the level of rescue
of glycemia, pointing to hyperglycemia as the controlling feature.
AB C
Figure 7. Increased a Cell Number and Plasma Glucagon in KATP-GOF Mice
(A) Representative images of double immunostaining for EGFP (indicating transgene expression in pancreatic b cells) and glucagon (Gcg) on pancreatic sections
from control and both untreated and insulin-treated KATP-GOF mice. White-bordered insets show costaining for both glucagon and EGFP.
(B and C) Quantification of glucagon-positive cells (B) and plasma glucagon (C) from control (black), KATP-GOF untreated (white), and KATP-GOF insulin-treated
(pink) mice (mean ± SEM). Data represent n = 5mice per group, five pancreatic sections per mouse. Significant differences: *p < 0.05, with respect to control, and
#p < 0.05, with respect to untreated KATP-GOF mice.
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Ngn3 staining (Figures 4 and 5), with maintenance of EGFP stain-
ing in the recovered islet cells (Figure 5), indicating that recovery
involves redifferentiation of the same former b cells within the
islet and with no evidence for transdifferentiation of dedifferenti-
ated b cells to a cells (Figure 7). This conclusion is supported by
the finding that, while multiple markers of cell dedifferentiation
are upregulated and specific b cell markers are reduced, in dia-
betic islets, all marker expression levels are restored to normal
after intensive insulin therapy (Figures 4 and S2). Essentially,
the same pattern of dedifferentiation and redifferentiation after
insulin therapy is demonstrated in diabetes driven by Rip-Cre-
induced expression of the sameKATP GOF transgene (Figure S3),
providing further evidence that resurgent b cells are derived from
the previously dedifferentiated b cells and excluding the possibil-
ity that these cells might be derived from ductal or acinar Pdx1-
positive cells in the Pdx-Cre-driven model. More generally, these
findings provide a potential explanation for the reversibility of b
cell dysfunction and restoration of drug responsivity that is
seen in human type 2 diabetics following b cell ‘‘rest’’ with inten-
sive insulin therapy (Alvarsson et al., 2008; Ilkova et al., 1997;
Torella et al., 1991; UK Prospective Diabetes Study Group,
1998b; Wajchenberg, 2007; Weng et al., 2008). They also raiseCthe exciting possibility that the gradual decrease in antidiabetic
drug responsivity that is frequently observed in diabetic patients
may similarly be reversed by intensive normalization of blood
glucose levels.
Conclusions
Our findings reveal a mechanism underlying loss of islet
insulin content in response to hyperglycemia in a mouse model
of KATP-dependent diabetes. These results might explain the
decrease in b cell mass in multiple forms of long-standing or
poorly controlleddiabetes. Theysuggest that targetingglucotoxic
b cell dysfunction and strictly normalizing blood glucose and
systemic diabetes could induce cell redifferentiation to mature
b cells and, hence, restoration of drug responsivity, providing an
approach to rescuing ‘‘exhausted’’ b cells in diabetes.
EXPERIMENTAL PROCEDURES
Chronic Insulin Therapy in a Mouse Model of Neonatal Diabetes
All experiments were performed in compliance with institutional guidelines and
approved by the Washington University Animal Studies Committee. Rip and
tamoxifen-inducible Pdx1PBCreERTM b cell-specific KATP gain-of-function
(Kir6.2 [K185Q,DN30]) mutant mice were previously generated. In the case
of inducible mice, transgene expression was induced by five consecutiveell Metabolism 19, 872–882, May 6, 2014 ª2014 Elsevier Inc. 879
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b Cell Dedifferentiation in Diabetesinjections of tamoxifen as described elsewhere (Remedi et al., 2009). Litter-
mate controls were used in all experiments. KATP-GOF transgenic mice with
severe diabetes (blood glucose >500 mg/dl) for several weeks were anesthe-
tized and implanted with time-release insulin pellets (release, 0.1 U/day per
implant for 60 days; Linbit, Linshin Canada Inc.), and blood glucose was
followed over time.
Blood Glucose, Plasma Insulin, Glucagon, and C-Peptide Levels
Tail bloodwasassayed for glucosecontent using theGlucometer Elite-Xl (Bayer
Corporation). The limit of detection was 600 mg/dl, and glucose at or above
this level was recorded as 600 mg/dl but considered to be a lower limit of the
true value. Plasma insulin was measured using the Singulex Erenna method
(Washington University Immunoassay Core), and glucagon was measured by
using radioimmunoassay (RIA,Millipore). C-peptidewasmeasured using ELISA
(Alpco Diagnostics, Washington University Immunoassay Core).
Pancreatic Islet Isolation
Mice were anesthetized with Isofluorane (0.2 ml) and killed by cervical disloca-
tion; the bile duct was cannulated and perfused with Hank’s solution (Sigma)
containing collagenase (Collagenase Type XI, Sigma). Pancreases were
removed and digested at 37C, hand shaken, and washed in cold Hank’s
solution. Islets were isolated by hand under a dissecting microscope and
maintained overnight in CMRL-1066 (5.6 mM glucose) culture medium
(GIBCO) supplemented with fetal calf serum (10%), penicillin (100 U/ml), and
streptomycin (100 mg/ml) (Remedi et al., 2009).
Insulin Secretion and Content
Following overnight incubation in low-glucose CMRL-1066 medium, islets (ten
per well in 12-well plates) were preincubated in glucose-free CMRL-1066 plus
3mM glucose (only for insulin secretion) and then incubated for 60min at 37C
in CMRL-1066 plus different glucose concentrations, 1 mM glibenclamide,
or 30 mM KCl, as indicated. After the incubation period, the medium was
removed and assayed for insulin release. Experiments were repeated in tripli-
cate. For islet insulin content, groups of five islets were disrupted using
ethanol-HCl extraction and sonicated on ice for estimation of insulin content.
Whole pancreas was removed and disrupted in homogenization buffer using a
polytron homogenizer. Samples were centrifuged, and supernatant was used
for measurement of total insulin content per pancreas. Insulin secretion and
content were measured using a rat insulin radioimmunoassay according to
manufacturer’s procedure (RIA, Millipore) (Remedi et al., 2009).
Immunohistochemical and Morphometric Analysis
Pancreases from control, untreated KATP-GOF (day 30 after tamoxifen induc-
tion) and insulin-treated KATP-GOF mice (day 70 after tamoxifen induction,
40 days after insulin pellet implantation) were fixed in 10% formalin and
paraffin embedded for sectioning. Four to eight mice from each genotype
were sampled on 5-mm-thick sections 150 mm apart and used for immunohis-
tochemical and morphometric analysis. For morphometric analysis, at least
five pancreatic sections from 3–5mice from each genotype were covered sys-
tematically by accumulating images from nonoverlapping fields on an inverted
fluorescence Zeiss microscope or on a Zeiss LSM 510 laser confocal micro-
scope. Hematoxylin and eosin staining was carried out as described else-
where (Remedi and Nichols, 2008). Antigen retrieval was performed for nuclear
transcription factor detection (Nacalai USA) (Talchai et al., 2012b). For insulin
positivity determination, islet insulin immunoreative cross-sectional area and
total pancreatic area were measured and calculated using MetaMorph imag-
ing software (Universal Imaging Corporation) and expressed as percentage of
b cell area relative to the total pancreatic area. Apoptosis was determined on
pancreatic paraffin sections by using TUNEL (ApopTag Plus Fluorescein In
Situ Apoptosis, Chemicon International, Inc.) and cleaved caspase-3 staining
techniques. Cleaved caspase-3 primary antibody (Cell Signaling) was de-
tected by using secondary antibody conjugated with Alexa 488 (green, Molec-
ular Probes). For apoptosis quantification, the number of TUNEL-positive cells
per total islet nuclei (counterstained with DAPI) or intra-islet caspase-3 inten-
sity per total islet area was determined. Quantification of Ngn3 was performed
in pancreatic sections double stained for insulin and Ngn3 by counting the
number of Ngn3-positive, insulin-negative, or insulin-positive cells in amerged
red and green image. The presence of EGFP (indicating KATP-GOF transgene880 Cell Metabolism 19, 872–882, May 6, 2014 ª2014 Elsevier Inc.expression on pancreatic b cells) was assessed in pancreatic sections using
EGFP primary antibody. Quantification of lineage tracing experiments in
KATP-GOF mice was performed by determining EGFP, insulin, and glucagon
immunoreactive areas and the ratio of overlapping area/total immunoreactive
area. Ngn3-positive cells were counted and expressed as a percentage of
Ngn3-positive cells per total EGFP immunoreactive area. To estimate a cell
population, the total number of glucagon-positive cells was counted from
several pancreatic sections immunostained for glucagon. For proliferation
analysis, Ki67-positive b cells were counted in pancreatic sections costained
for insulin and expressed as a percentage of Ki67-positive cells per total b
cell area. Primary antibodies used were as follows: insulin (rabbit monoclonal,
Cell Signaling; or guinea pig polyclonal, Abcam), neurogenin3 (goat polyclonal
for the N terminus of Ngn3, Santa Cruz; Figures 4 and 5), Beta Cell Biology
Consortium (BCBC) (mouse BCBC F25A1B3; Figure S2A), EGFP (rabbit poly-
clonal, Molecular Probes, Invitrogen), glucagon (guinea pig polyclonal, Milli-
pore), Ki67 (rabbit polyclonal, Abcam), Nanog (rabbit polyclonal, Abcam),
Oct4 (rabbit polyclonal, Stemgent), and Nestin (mouse monoclonal, Abcam).
Detection was performed by using secondary antibody conjugated with Alexa
488 (green) or Alexa 594 (red) fluorescent dyes (Molecular Probes) (Remedi
et al., 2009).
Quantitative RT-PCR Analysis
Islets were isolated 30 days after tamoxifen injection and 70 days after tamox-
ifen (40 days after insulin pellet implantation) for KATP-GOF-untreated and in-
sulin-treatedmice, respectively, and immediately processed for RNA isolation.
Cellular RNA was isolated using the RNeasy Mini Kit (QIAGEN), and DNA was
removed using DNase1 RNase-Free solution (QIAGEN). cDNA was prepared
from RNA using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems), and quantitative RT-PCR was performed using the One-Step
system and Taq-Man primers (Applied Byosystems). The experimental data
were normalized using two reference genes: b-actin for high abundant genes
and b-actin and TATA binding protein for low abundant genes. mRNA changes
were calculated by the comparative DCt method.
Statistics
Data are presented as means ± SEM. Differences between two groups were
tested using t test and differences among several groups were tested using
an ANOVA and post hoc Duncan’s test.
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